$2.59 Billion is the total value of Tekla Capital Management LLC's 161 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BMY | New | Bristol-Myers Squibb Company | $21,394,000 | – | 349,121 | +100.0% | 0.82% | – |
| SAGE | New | Sage Therapeutics, Inc. | $11,170,000 | – | 67,815 | +100.0% | 0.43% | – |
| AET | New | Aetna Inc. | $8,580,000 | – | 47,566 | +100.0% | 0.33% | – |
| ALKS | New | Alkermes plcshares | $7,885,000 | – | 144,072 | +100.0% | 0.30% | – |
| ACAD | New | ACADIA Pharmaceuticals Inc. | $7,404,000 | – | 245,885 | +100.0% | 0.29% | – |
| BSX | New | Boston Scientific Corporation | $6,559,000 | – | 264,600 | +100.0% | 0.25% | – |
| IONS | New | Ionis Pharmaceuticals, Inc. | $6,485,000 | – | 128,930 | +100.0% | 0.25% | – |
| GWPH | New | GW Pharmaceuticals plcads | $3,300,000 | – | 25,000 | +100.0% | 0.13% | – |
| CYTK | New | Cytokinetics, Inc. | $2,855,000 | – | 350,300 | +100.0% | 0.11% | – |
| LXRX | New | Lexicon Pharmaceuticals, Inc. | $2,754,000 | – | 278,700 | +100.0% | 0.11% | – |
| PHG | New | Koninklijke Philips N.V.ny registry shares | $2,646,000 | – | 70,000 | +100.0% | 0.10% | – |
| BGNE | New | BeiGene, Ltd.sponsored adr | $2,557,000 | – | 26,170 | +100.0% | 0.10% | – |
| TXMD | New | TherapeuticsMD, Inc. | $2,537,000 | – | 420,000 | +100.0% | 0.10% | – |
| DHR | New | Danaher Corporation | $1,411,000 | – | 15,203 | +100.0% | 0.05% | – |
| ISRG | New | Intuitive Surgical, Inc. | $1,405,000 | – | 3,850 | +100.0% | 0.05% | – |
| SNN | New | Smith & Nephew plcsponsored adr | $1,407,000 | – | 40,183 | +100.0% | 0.05% | – |
| RVNC | New | Revance Therapeutics, Inc. | $1,152,000 | – | 32,225 | +100.0% | 0.04% | – |
| ALQA | New | Alliqua BioMedical, Inc. | $302,000 | – | 165,000 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Gilead Sciences, Inc. | 41 | Q2 2023 | 12.4% |
| Amgen, Inc. | 41 | Q2 2023 | 5.8% |
| Biogen Inc. | 41 | Q2 2023 | 6.5% |
| Vertex Pharmaceuticals Incorporated | 41 | Q2 2023 | 5.3% |
| Regeneron Pharmaceuticals, Inc. | 41 | Q2 2023 | 9.1% |
| Illumina, Inc. | 41 | Q2 2023 | 3.4% |
| BioMarin Pharmaceutical Inc. | 41 | Q2 2023 | 2.9% |
| Teva Pharmaceutical Industries Ltd. | 41 | Q2 2023 | 3.2% |
| Neurocrine Biosciences, Inc. | 41 | Q2 2023 | 1.4% |
| McKesson Corporation | 41 | Q2 2023 | 2.2% |
View Tekla Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Rallybio Corp | January 23, 2023 | 1,727,067 | 4.6% |
| Zyla Life SciencesSold out | January 29, 2021 | 0 | 0.0% |
| ARCA biopharma, Inc. | January 24, 2020 | 36,068 | 2.3% |
| Verona Pharma plc | February 12, 2019 | 5,296,845 | 4.9% |
| Alliqua BioMedical, Inc. | February 12, 2018 | 165,000 | 3.3% |
| PIERIS PHARMACEUTICALS, INC. | February 12, 2018 | 1,962,380 | 4.4% |
| Intellipharmaceutics International Inc. | February 13, 2015 | 2,184,000 | 9.0% |
| HERON THERAPEUTICS, INC. /DE/ | February 14, 2014 | 20,598,613 | 4.2% |
| MEDWAVE INC | February 14, 2012 | 1,277,372 | 9.8% |
| MZT Holdings, Inc. | February 14, 2012 | 2,553,420 | 4.0% |
View Tekla Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-10 |
| SC 13G/A | 2023-01-23 |
| 13F-HR | 2022-11-01 |
| 13F-HR | 2022-07-29 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| SC 13G | 2022-01-21 |
| 13F-HR | 2021-11-12 |
View Tekla Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.